Spectrum of use for the angiotensin-receptor blocking drugs

Current Hypertension Reports

Volumn 1, Issue 5, 1999, Pages 394-401

  Fabiani, Maurice E ^a   Johnston, Colin I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; BLOOD; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; VASOCONSTRICTION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; HUMANS; HYPERTENSION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME; VASOCONSTRICTION;

EID: 0033205253     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-999-0054-1     Document Type: Article

References (85)

1. Johnston CI: Franz Volhard lecture: renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens 1992, 10(suppl7):S13-S26.
2. Dzau VJ: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988, 77(pt 2):I4-I13.
3. Urata H, Nishimura H, Ganten D: Mechanisms of angiotensin II formation in humans. Eur Heart J 1995, 16(suppl N):79-85.
4. Urata H, Nishimura H, Ganten D, Arakawa K: Angiotensinconverting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. Blood Press 1996, 2(suppl):22-28.
5. Griendling KK, Lassegue B, Alexander RW: Angiotensin receptors and their therapeutic implications. Ann Rev Pharmacol Toxicol 1996, 36:281-306.
6. Ardaillou R: Angiotensin II receptors. J Am Soc Nephrol 1999, 10(suppl 11):S30-S39.
7. Timmermans PB, Wong PC, Chiu AT, et al.: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993, 45:205-251.
8. Iwai N, Inagami T: Identification of two subtypes in the rat type I angiotensin II receptor. FEBS Lett 1992, 298:257-260.
9. Yoshida H, Kakuchi J, Guo DF, et al.: Analysis of the evolution of angiotensin II type 1 receptor gene in mammals (mouse, rat, bovine and human). Biochem Biophys Res Commun 1992, 186:1042-1049.
10. Furuta H, Guo DF, Inagami T: Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1992, 183:8-13.
11. Takayanagi R, Ohnaka K, Sakai Y, et al.: Molecular cloning, sequence analysis and expression of a cDNA encoding human type-1 angiotensin II receptor. Biochem Biophys Res Commun 1992, 183:910-916.
12. Bergsma DJ, Ellis C, Kumar C, et al.: Cloning and characterization of a human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1992, 183:989-995.
13. Szpirer C, Riviere M, Szpirer J, et al.: Chromosomal assignment of human and rat hypertension candidate genes: type 1 angiotensin II receptor genes and the SA gene. J Hypertens 1993, 11:919-925.
14. Lewis JL, Serikawa T, Warnock DG: Chromosomal localization of angiotensin II type 1 receptor isoforms in the rat. Biochem Biophys Res Commun 1993, 194:677-682.
15. Tissir F, Riviere M, Guo D F, et al.: Localization of the genes encoding the three rat angiotensin II receptors, Agtr1a, Agtr1b, Agtr2, and the human AGTR2 receptor respectively to rat chromosomes 17q12, 2q24 and Xq34, and the human Xq22. Cytogenet Cell Genet 1995, 71:77-80.
16. Murphy TJ, Takeuchi K, Alexander RW: Molecular cloning of AT1 angiotensin receptors. Am J Hypertens 1992, 5(pt 2):236S-242S.
17. Martin MM, Su B, Elton TS: Molecular cloning of the human angiotensin II type 2 receptor cDNA. Biochem Biophys Res Commun 1994, 205:645-651.
18. Martin MM, Su B, Elton TS: Molecular cloning of the human AT 2 receptor. Adv Exp Med Biol 1996, 396:153-165.
19. Koike G, Horiuchi M, Yamada T, et al.: Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung. Biochem Biophys Res Commun 1994, 203:1842-1850.
20. Mukoyama M, Nakajima M, Horiuchi M, et al.: Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993, 268:24539-24542.
21. Chung O, Kuhl H, Stoll M, Unger T: Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int 1998, 67(suppl):S95-S99.
22. Csikos T, Chung O, Unger T: Receptors and their classification: focus on angiotensin II and the AT2 receptor. J Hum Hypertens 1998, 12:311-318.
23. Johnston CI: Angiotensin receptor antagonists: focus on losartan. Lancet 1995, 346:1403-1407.
24. Burnier M, Brunner HR: Angiotensin II receptor antagonists in hypertension. Kidney Int 1998, 68(suppl):S107-S111. A recent review on angiotensin II receptor antagonists and their use in the treatment of hypertension.
25. Minghelli G, Seydoux C, Goy JJ, Burnier M: Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998, 66:268-271.
26. Semple PF: Putative mechanisms of cough after treatment with angiotensin-converting enzyme inhibitors. J Hypertens 1995, 13(suppl):S17-S21.
27. Overlack A: ACE inhibitor-induced cough and bronchospasm: incidence, mechanisms and management. D ru g Saf 1996, 15:72-78.
28. Pylypchuk GB: ACE inhibitor-versus angiotensin II blockerinduced cough and angioedema. Ann Pharmacother 1998, 32:1060-1066.
29. Voors AA, Pinto YM, Buikema H, et al.: Dual pathway for angiotensin II formation in human internal mammary arteries. Br J Pharmacol 1998, 125:1028-1032.
30. Johnston CI, Naitoh M, Burrell LM: Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues. J Hypertens 1997, 15(suppl):S3-S6. A review outlining the pharmacology of angiotensin II receptor antagonists and the rationale for their use as antihypertensive agents.
31. Johnston CI, Risvanis J: Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. Am J Hypertens 1997, 10(pt 2):306S-310S.
32. McIntyre M, Caffe SE, Michalak RA, Reid JL: Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997, 74:181-194.
33. Markham A, Goa KL: Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997, 54:299-311.
34. Brown MJ: Irbesartan treatment in hypertension. Hosp Med 1998, 59:808-811.
35. McClellan KJ, Goa KL: Candesartan cilexetil: a review of its use in essential hypertension. Drugs 1998, 56:847-869.
36. Tikkanen I, Omvik P, Jensen HA: Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995, 13:1343-1351.
37. Townsend R, Haggert B, Liss C, Edelman JM: Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther 1995, 17:911-923.
38. Oparil S, Barr E, Elkins M, et al.: Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 1996, 18:608-625.
39. Weir MR, Elkins M, Liss C, et al.: Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996, 18:411-428.
40. Conlin PR, Elkins M, Liss C, et al.: A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension. J Hum Hypertens 1998, 12:693-699.
41. Chan JC, Critchley JA, Lappe JT, et al.: Randomised, doubleblind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995, 9:765-771.
42. Dahlof B, Keller SE, Makris L, et al.: Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995, 8:578-583.
43. Roca-Cusachs A, Oigman W, Lepe L, et al.: A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. Acta Cardiol 1997, 52:495-506.
44. Kassler-Taub K, Littlejohn T, Elliott W, et al.: Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens 1998, 11(part 1):445-453.
45. Oparil S, Guthrie R, Lewin AJ, et al.: An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators. Clin Ther 1998, 20:398-409.
46. Andersson OK, Neldam S: The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998, 7:53-59.
47. MacKay JH, Arcuri KE, Goldberg AI, et al.: Losartan and lowdose hydrochlorothiazide in patients with essential hypertension: a double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996, 156:278-285.
48. Ruilope LM, Simpson RL, Toh J, et al.: Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press 1996, 5:32-40.
49. Gigante B, Piras O, De Paolis P, et al.: Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens 1998, 16(part 2):2039-2043. This study shows that in the salt-restricted rat blockade of AT2 receptors with PD123319 increases blood pressure and offsets the blood pressure lowering effect of losartan.
50. Dahlof B, Devereux R, De Faire U, et al.: The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997, 10(part 1):705-713.
51. Mann J, Julius S: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension: rationale and design. Blood Press 1998, 7:176-183.
52. Schrader J, Rothemeyer M, Luders S, Kollmann K: Hypertension and stroke: rationale behind the ACCESS trial. Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Basic Res Cardiol 1998, 93(suppl 2):69-78.
53. Crozier I, Ikram H, Awan N, et al.: Losartan in heart failure: hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation 1995, 91:691-697.
54. Mazayev VP, Fomina IG, Kazakov EN, et al.: Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int J Cardiol 1998, 65:239-246.
55. Lang RM, Elkayam U, Yellen LG, et al.: Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol 1997, 30:983-991.
56. Hamroff G, Blaufarb I, Mancini D, et al.: Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure. J Cardiovasc Pharmacol 1997, 30:533-536.
57. Pitt B, Segal R, Martinez FA, et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997, 349:747-752. This paper reports an apparent greater reduction in mortality in elderly patients with congestive heart failure receiving losartan compared to captopril.
58. Tsuyuki RT, Yusuf S, Rouleau JL, et al.: Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997, 13:1166-1174.
59. Yusuf S, Maggioni AP, Held P, Rouleau JL: Effects of candesartan, enalapril, or their combination on exercise capacity, ventricular function, clinical deterioration and quality of life in heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study [abstract]. Circulation 1997, 96:2527.
60. Yusuf S: Phase I results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) trial. Am J Managed Care 1998, 4(suppl S):S380-S383. A pilot heart failure study that was stopped prematurely due to an apparent (non-significant) increase in mortality in patients receiving candesartan cilexetil alone or in combination with enalapril compared to enalapril alone.
61. Dahlof B: Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy. Blood Press 1994, 2(suppl):35-40.
62. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996, 275:1507-1513.
63. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P: Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998, 13:564-569.
64. Tedesco MA, Ratti G, Aquino D, et al.: Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998, 12:505-510.
65. Thurmann PA, Kenedi P, Schmidt A, et al.: Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998, 98:2037-2042.
66. Kahan T: The importance of left ventricular hypertrophy in human hypertension. J Hypertens 1998, 16(suppl 7):S23-S29.
67. Kahan T, Malmqvist K, Edner M, et al.: Rate and extent of left ventricular hypertrophy regression: a comparison of angiotensin II blockade with irbesrtan and beta-blockade [abstract]. J Am Coll Cardiol 1998, 31:212.
68. Cohen A, Bregman B, Agabiti Rosei E, et al.: Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression. J Hum Hypertens 1998, 12:479-483.
69. Dahlof B, Devereux RB, Julius S, et al.: Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998, 32:989-997.
70. Wolf G: Angiotensin II: a pivotal factor in the progression of renal diseases. Nephrol Dial Transplant 1999, 14(suppl 1):42-44.
71. Maschio G, Alberti D, Janin G, et al.: Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996, 334:939-945.
72. Antonios T F, MacGregor GA: Angiotensin converting enzyme inhibitors in hypertension: potential problems. J Hypertens 1995, 13(suppl 3):S11-S16.
73. Nielsen S, Dollerup J, Nielsen B, et al.: Losartan reduces albuminuria in patients with essential hypertension: an enalapril controlled 3 months study. Nephrol Dial Transplant 1997, 12(suppl 2):19-23.
74. Fernandez-Andrade C, Russo D, Iversen B, et al.: Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int 1998, 68(suppl):S120-S124.
75. Buter H, Navis G, De Zeeuw D, De Jong PE: Renal hemodynamic effects of candesartan in normal and impaired renal function in humans. Kidney Int 1997, 63(suppl):S185-187.
76. Plum J, Bunten B, Nemeth R, Grabensee B: Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998, 9:2223-2234.
77. Goldberg AI, Dunlay MC, Sweet CS: Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995, 75:793-795.
78. Belcher G, Hubner R, George M, et al.: Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997, 11(suppl 2):S85-S89.
79. Simon TA, Gelarden RT, Freitag SA, et al.: Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol 1998, 82:179-182.
80. Paster RZ, Snavely DB, Sweet AR, et al.: Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors. Clin Ther 1998, 20:978-989.
81. Van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J: Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998, 158:2063-2065. A review of some case reports of angioedema associated with the use of losartan.
82. Frye CB, Pettigrew TJ: Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy 1998, 18:866-868.
83. Sharma PK, Yium JJ: Angioedema associated with angiotensin II receptor antagonist losartan. South Med J 1997, 90:552-553.
84. Acker CG, Greenberg A: Angioedema induced by the angiotensin II blocker losartan. N Engl J Med 1995, 333:1572.
85. Mastrobattista JM: Angiotensin converting enzyme inhibitors in pregnancy. Semin Perinatol 1997, 21:124-134.